BioSpace News Archive

aTyr Pharma, Inc., a clinical stage biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, announced that it has commenced an underwritten public offering of shares of its common stock.

Today, the U.S. Food and Drug Administration announced the reorganization of the agency’s information technology (IT), data management and cybersecurity functions into the new Office of Digital Transformation (ODT).

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today highlighted a new analysis suggesting that the Moderna COVID-19 vaccine is highly effective against circulating variants of concern, including in a vaccine effectiveness study conducted in partnership with Kaiser Permanente Southern California (KPSC) and in a separate recent publication by the U.S. Centers for Disease Control and Prevention (CDC)

Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that the Company will host a virtual Investor Event on Monday, September 20, 2021 at 8:30 a.m. ET / 5:30 a.m. PT.

Protagonist Therapeutics, Inc. reported that on September 15, 2021, it issued inducement awards to two recently hired employees in accordance with the terms of their employment offer letters.

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the U.S. Food and Drug Administration (FDA) has approved EXKIVITY

Obsidian Therapeutics, a biotechnology company pioneering engineered cell and gene therapies, announced that the Company will present data highlighting its cytoTIL15™ program at the upcoming European Society for Medical Oncology Congress, which will be hosted virtually September 16-21, 2021.

The U.S. Food and Drug Administration has granted premarket approval to Thermo Fisher Scientific’s Oncomine Dx Target Test as a companion diagnostic to identify patients with epidermal growth factor receptor Exon20 insertion mutation-positive metastatic non-small cell lung cancer who are candidates for EXKIVITY™, a targeted drug developed by Takeda Pharmaceutical Company Limited.

GeneQuantum Healthcare announced the appointment of Dr. Li Wan as the Senior Vice President and Head of Global Regulatory Affairs, Dr. Weimeng Zhao as Vice President of Quality Research and Quality, to further strengthen the GeneQuantum management team.

In conjunction with Living Donation Week, Astellas Pharma Canada, Inc. is proud to announce it has been named as a new member of the Canadian Society of Transplantation’s (CST) Living Donor Circle of Excellence Program